SCHEMBL12416701

SCHEMBL12416701

COc1ccc2cc(C(C)C)cnc2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.40
KMT2A Q03164 1/20 0.40
HPGDS O60760 1/20 0.38
PIK3CA P42336 2/20 0.38
PTGS2 P35354 3/20 0.35
AKR1C3 P42330 3/20 0.35
AKR1C2 P52895 3/20 0.35
PTGS1 P23219 2/20 0.35
TSHR P16473 2/20 0.35
CDC42 P60953 1/20 0.35
RAC1 P63000 1/20 0.35
SLC22A6 Q4U2R8 1/20 0.35
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12939768 0.79 HPGDS (0.41) KMT2AHPGDSMAPT
SCHEMBL22509842 0.77 DHFR (0.38)
SCHEMBL13458729 0.77 CCR1 (0.50) CYP1A2KMT2AHPGDSPIK3CATUBB4A
SCHEMBL23775719 0.75 DHFR (0.35)
SCHEMBL14288343 0.74 CDK4 (0.41) CYP1A2PTGS2AKR1C3AKR1C2PTGS1
SCHEMBL2609318 0.74 OXTR (0.46) KMT2AMAPTTUBB4ATUBBTUBA3C
SCHEMBL16705355 0.72 CYP1A2 (0.40) CYP1A2KMT2AHPGDSPIK3CAPTGS2
SCHEMBL12416723 0.72 NPC1 (0.39) CYP1A2PTGS2AKR1C3AKR1C2PTGS1
SCHEMBL12546135 0.71 MTNR1A (0.42) CYP1A2KMT2AAKR1C3AKR1C2LMNA
SCHEMBL2611069 0.71 CCR1 (0.40) MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436015-B2 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use MERCK SHARP & DOHME CORP. (US) 2013-05-07 US disclosed
US-20110172256-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME LLC 2011-07-14 US disclosed
US-20110172256-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME LLC 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172256-A1 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE GCGR, GLP1R, GPR119 CYP1A2 1996/4885KMT2A 4294/4885HPGDS 570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.